Basalzellkarzinom: A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study

Stadium/Indikation inkl. Kurzinfo

Lymphom / BCC

Vorbehandelte Mycosis fungoides Stadium IIB-IVB oder Sézary Syndrom

Resminostat vs Placebo (Rollover möglich)

Kurztitel

4SC-201-6-2015 (RESMAIN)
NCT02953301

Offizieller Titel

A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study